Search
Displaying 71–80 of 532 for “Retinitis pigmentosa”
-
Eye on the Cure Podcast | Episode 67: Dr. Peter Campochiaro
Eye on the CureDr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.
-
Foundation News
Advancing Research Solutions for PRPH2-Associated Retinal Diseases.
-
ARVO 2024 Highlight: Positive Two-Year Results from PDE6B Gene Therapy Clinical Trial
Research NewsMutations in PDE6B are a leading cause of retinitis pigmentosa.
-
VISIONS 2024, the global conference (June 20–21, 2024) of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
What Does “Blindness” Really Mean?
Beacon StoriesJenny Schisler has retinitis pigmentosa. Jenny wants to spread awareness of what having a visual impairment really means to her and others affected by retinal degenerative diseases.
-
Eye on the Cure Podcast | Episode 58: Jason Comander
Eye on the CureJason Comander, Md, PhD, clinical researcher, surgeon, and director of the Inherited Retinal Disease Disorders Service at Mass Eye and Ear, talks to host Ben Shaberman about his administration of LUXTURNA gene therapy to RPE65 patients, his team’s re-analysis of vitamin A therapy for retinitis pigmentosa, and passion for retinal research and patient care.
-
Eye on the Cure Podcast | Episode 56: Michael Voevodsky, MBA, CEO
Eye on the CureMichael Voevodsky, MBA, CEO at MitoChem Therapeutics, talks to host Ben Shaberman about his company’s emerging, gene-agnostic treatment designed to boost mitochondrial function for preserving vision in people with retinitis pigmentosa, age-related macular degeneration, and other retinal conditions.
-
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
Research NewsThe company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
Finding the “Keys to the Kingdom”
Beacon StoriesTricia Waechter, who has retinitis pigmentosa (RP), refers to her white canes as the “keys to the kingdom.” Using a white cane has opened a whole new world for Tricia, and that is why her company, Blind Girl Designs, includes white canes on many of their apparel designs.
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2023 (July 1, 2022–June 30, 2023)
.png)
%20(13).png)
